Cart
sales@molnova.com
Navitoclax
CAS No. 923564-51-6
Navitoclax( ABT-263 | ABT 263 | ABT263 )
Catalog No. M16614 CAS No. 923564-51-6
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 37 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 133 | In Stock |
|
| 100MG | 177 | In Stock |
|
| 200MG | 259 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNavitoclax
-
NoteResearch use only, not for human use.
-
Brief DescriptionNavitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
-
DescriptionNavitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w; binds more weakly to Mcl-1 and A1 (Ki>350 nM); disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines (EC50<1 uM); induces complete tumor regressions in xenograft models of NSCLA and ALL.Blood Cancer Phase 2 Clinical.
-
In Vitro——
-
In VivoAnimal Model:Mice with NCI-H1650 modelDosage:100 mg/kg Administration:Orally; daily; for 21 consecutive days Result:As a single agent, 100 mg/kg alone dosed daily had no significant antitumor activity. Notably, the combination with OSI-744 resulted in 98% TGI and durable tumor regressions in 100% of treated tumor-bearing mice.
-
SynonymsABT-263 | ABT 263 | ABT263
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2|Bcl-w|Bcl-xL
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number923564-51-6
-
Formula Weight974.6127
-
Molecular FormulaC47H55ClF3N5O6S3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
-
Chemical NameBenzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8.
2. Shoemaker AR, et al. Clin Cancer Res. 2008 Jun 1;14(11):3268-77.
3. Ackler S, et al. Mol Cancer Ther. 2008 Oct;7(10):3265-74.
4. Shah OJ, et al. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9.
molnova catalog
related products
-
BM-957
BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.
-
Isoverticine
Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.
-
Bcl-xL antagonist 2
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
